AP
RETA

Atlas Principals’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Atlas Principals’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-10,000
Closed -$1.56M – 45
2020
Q2 		$1.56M Buy
10,000
+5,000
+100% +$760K 1.16% 27
2020
Q1 		$722K Buy
+5,000
New +$965K 0.69% 30

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Atlas Principals's RETA Position: Q3 2020 in Review

Atlas Principals sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2020, closing a stake of 10,000 shares — an estimated $1.56M sold.

Atlas Principals first reported a position in RETA in Q1 2020 and held it in 2 quarters. The position peaked at $1.56M in Q2 2020. 186 funds tracked by Wall St. Rank hold RETA as of Q3 2020.

  • Atlas Principals reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2020 after selling out during the quarter.
  • Atlas Principals sold 10,000 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2020, an estimated $1.56M.
  • Atlas Principals first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2020 and held it in 2 quarters.
  • Atlas Principals's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.56M in Q2 2020.
  • 186 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2020.

Based on Atlas Principals's 13F filing for Q3 2020, filed 16 Nov 2020.